Boehringer Ingelheim Opens New Production Plant in China

04-Mar-2002

Ingelheim, Germany/ Shanghai, China, 4th March, 2002 - Boehringer Ingelheim's operating unit Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd in China officially opened today a new manufacturing facility in Pudong Zhangjiang High Tech. Park in Shanghai. The whole plant covers an area of 34,570 m2, while the main buildings cover 5,330 m2. The estimated production capacity will be 150 million tablets, 6.2 million metered dose inhalers, 10 million bottles of liquid pharmaceuticals and 11.7 million unit dose vials every year.

"We are very pleased with this new production plant, because it will give us the opportunity to supply the huge Chinese market with our innovative pharmaceuticals. I would like to thank our Chinese partners and the authorities involved for their reliable cooperation which enabled us to finish this project in a reasonably short time span," said Prof. Rolf Krebs, Chairman of the Board of Managing Directors of Boehringer Ingelheim.

Dr. Hans-Jürgen Leuchs, responsible for production and technology in the Boehringer Ingelheim Board commented: "It was our intention to have a production facility on the Chinese market which can produce all important dosage forms for this market. This further strengthens our network of pharmaceutical plants in Japan, Indonesia, Taiwan and South Korea."

In July 1998, Boehringer Ingelheim received construction approval from the National Pharmaceutical Supervision Bureau. One year later, the construction plans were complete and the German construction company HOLZMANN was selected as general contractor. Building started in November 1999.

The total project called for an investment of USD 41 million, approximately 45.7 million Euro. The municipal government holds the project in high esteem, listing it as one of the significant projects in Shanghai industry.

Mr Peter Bohnekamp, Country Manager of Boehringer Ingelheim China commented: "In the past years, our business has grown at an even faster pace than China and Shanghai. We have emphasized our commitment to China by setting up our manufacturing facility in Medicine Valley in Shanghai Pudong. This will allow us to strengthen our presence and build up a more competitive Boehringer Ingelheim China by providing state of the art technology and manufacturing. This shall also result in bringing better quality of life to patients and employees."

Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd. is a joint venture between Boehringer Ingelheim International GmbH and Shanghai Sine Pharmaceutical Co., Ltd. Boehringer Ingelheim holds 95% of the stakes.

https://www.chemeurope.com/en/news/9022/boehringer-ingelheim-opens-new-production-plant-in-china.html